Owlstone’s Breath Biopsy technology analyses VOCs in breath samples. Credit: Owlstone Medical.

Breath Biopsy solutions provider Owlstone Medical has raised a total of $58m in a Series D financing round.

The round was led by returning investor Horizons Ventures. Several existing and new investors also joined.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The latest fundraising brings the total amount raised by Owlstone Medical from the market to more than $150m.

The UK-based company has developed a platform in Breath Biopsy for use in routine diagnostic testing and biomarker discovery.

Currently, Owlstone Medical offers research products and services to pharmaceutical and academic organisations. It also has a pipeline of research use only (RUO) panels and diagnostic tests in development for lung cancer, liver disease and respiratory disease.

Owlstone plans to use the new proceeds to support the development and commercialisation of these tests. A portion of the new funding will also be used to enhance the Breath Biopsy platform.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Owlstone Medical co-founder and CEO Billy Boyle said: “Owlstone Medical continues to make tremendous progress, including major advancements in our Breath Biopsy platform, such as the development of EVOC Probes; strong progress in our test pipeline with the launch of the Respiratory Diseases RUO Panel and the publication of key study results for liver disease; and entering into a partnership with Functional Gut Diagnostics for the provision of clinical tests for small intestinal bacterial overgrowth (SIBO) and food intolerance.

“We are thrilled to have the support of such highly respected investors as we strive to have a major impact on patient outcomes and the efficient delivery of healthcare resources and are very pleased to now welcome the experience and insight of Horizons’ Patrick Zhang to our board.”

 

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact